Purchase Order 75F40126P00156

Naval Sea Systems Command awarded a purchase order to VHG Labs Inc. for $2,663.00 on February 1, 2026, for custom standard MOM #1, Allen #10, and yttrium standard, with completion by February 4, 2026. Place of performance is Portsmouth, Virginia. The order is firm fixed price with no set-aside designation. VHG Labs, a Manchester, New Hampshire–based chemical standards and reference materials manufacturer, supplies specialized analytical products and certified reference materials to federal...

<p>The Food and Drug Administration issued a delivery order to Government Scientific Source Inc., a small business, on July 10, 2026, with a ceiling value of $59,493.05 under the GSA Multiple Award Schedule (MAS) for Promega luciferase assay systems and FuGene 6 transfection reagents.</p> <p>Place of performance is Reston, VA 20191. The order is firm fixed price with an ultimate completion date of August 9, 2026. No set-aside was used.</p>

<p>The Food and Drug Administration awarded a purchase order to Element Materials Technology Holding USA Inc. for $38,860 on September 10, 2024, to screen sterile over-the-counter monograph drug products for microbial contamination as part of the FY26 UDO Initiative. Work is performed in Hamilton, Ohio, with an ultimate completion date of September 29, 2025. The order carries no set-aside designation and is priced on a firm fixed-price basis.</p>

The U.S. Food and Drug Administration (FDA), an agency of the Department of Health and Human Services (HHS), has awarded a firm fixed-price purchase order valued at $25,749.97 to Agilent Technologies Inc. for a CFSAN-2023-118815-BNE-GC-MSMS flow modulator. The contract period of performance runs from July 19, 2023 through September 29, 2024. As the prime contractor, Agilent Technologies Inc. will deliver the specified flow modulator to the FDA's Center for Food Safety and Applied Nutrition...

The Food and Drug Administration awarded a purchase order to 28Bio, Inc. for $143,020.98 to conduct central nervous system 3D brain organoid neuropharmacological analysis under Executive Order 14398, with an award date of August 1, 2026 and completion date of April 30, 2027. Performance takes place in Metairie, Louisiana. The work involves functional examination of neuromodulatory effects of a marketed small molecule drug using human CNS 3D brain organoids, including acute and chronic...

<p>The Food and Drug Administration issued a delivery order to We Pharma, Inc. on July 28, 2025, with a ceiling value of $1.507 million for currently marketed drug products supporting FDA research studies under the GDUFA regulatory science program within the Office of Pharmaceutical Quality Research.</p> <p>Place of performance is Takoma Park, MD. The order carries a firm fixed price and extends through August 6, 2030. We Pharma, Inc. is a self-certified small disadvantaged business.</p>

The Department of Health and Human Services Food and Drug Administration awarded a $69,712 delivery order against the Multiple Award Schedule contract vehicle to Government Scientific Source Inc., doing business as G S S. The firm fixed price order is to provide obsolete laboratory water purification systems for the agency. Performance will take place in Winchester, Massachusetts over a one year period from September 2023 through September 2024. No set aside designation or subcontractors were...

The Food and Drug Administration issued a delivery order to the New Hampshire Liquor Commission on May 30, 2026, with a ceiling value of $313,678.80 for tobacco inspection and compliance activities in New Hampshire. This delivery order is issued under an FDA indefinite delivery contract valued at $2,247,107.00 (awarded September 25, 2024, completion September 28, 2029) that supports the FDA's tobacco regulation and enforcement efforts through ongoing compliance monitoring and retail inspections....

This purchase order was awarded by the Department of Justice Drug Enforcement Administration to VHG Labs Inc. to fulfill orders for items needed to support the agency's SFL4, Nitazene research and SFL10 programs. With a potential value of ten thousand nine hundred thirty-three dollars and no set-aside designation, the firm fixed price contract runs through January 9, 2025 and was awarded on January 10, 2024. The place of performance will be Sterling, Virginia. No major subcontractors were...

<p>The Food and Drug Administration awarded a purchase order to Bioivt, LLC for cryopreserved hepatocytes on August 17, 2023, with a ceiling value of $16,179.20. Performance takes place in Silver Spring, Maryland. The order, issued as a firm fixed-price acquisition with no set-aside designation, has an ultimate completion date of August 16, 2024.</p>